To include your compound in the COVID-19 Resource Center, submit it here.

FDA panel to probe safety of Dynavax HBV vaccine

In briefing documents released ahead of an advisory committee meeting to discuss an NDA for Heplisav-B from Dynavax Technologies Corp. (NASDAQ:DVAX), FDA reviewers said the vaccine

Read the full 264 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE